Generic Name and Formulations:
Ganciclovir 4.5mg; per implant; for intravitreal implantation.
Bausch Health Companies Inc.
Indications for VITRASERT:
Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
Adults and Children:
<9yrs: not recommended. ≥9yrs: Implant designed to release drug over 5–8 months. May be removed and replaced following depletion of ganciclovir.
External infection. Severe thrombocytopenia.
Should be administered by surgeon who has observed or assisted in surgical implantation of Vitrasert prior to attempting procedure. Monitor for extraocular CMV disease. Ophthalmologic follow-up advised at appropriate intervals. Pregnancy (Cat.C). Nursing mothers: not recommended.
Visual acuity loss of 3 lines or more, vitreous hemorrhage, retinal detachments, cataract formation/lens opacities, macular abnormalities, intraocular pressure spikes, optic disk/nerve changes, hyphemas, uveitis.